Veradermics, Incorporated (MANE) - Total Liabilities
Based on the latest financial reports, Veradermics, Incorporated (MANE) has total liabilities worth $6.72 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Veradermics, Incorporated's assets to evaluate the company's liquid asset resilience ratio.
Veradermics, Incorporated - Total Liabilities Trend (2023–2025)
This chart illustrates how Veradermics, Incorporated's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Veradermics, Incorporated.
Veradermics, Incorporated Competitors by Total Liabilities
The table below lists competitors of Veradermics, Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JHT Design Co. Ltd. Cl A
SHG:603061
|
China | CN¥648.97 Million |
|
Trex Company Inc
NYSE:TREX
|
USA | $734.05 Million |
|
Allete Inc
NYSE:ALE
|
USA | $3.81 Billion |
|
Sezzle Inc.
NASDAQ:SEZL
|
USA | $223.50 Million |
|
CECO Environmental Corp.
NASDAQ:CECO
|
USA | $1.65 Billion |
|
Grand Canyon Education Inc
NASDAQ:LOPE
|
USA | $249.67 Million |
|
Micro-Star International Co Ltd
TW:2377
|
Taiwan | NT$66.35 Billion |
|
Oscar Health Inc
NYSE:OSCR
|
USA | $5.34 Billion |
Liability Composition Analysis (2023–2025)
This chart breaks down Veradermics, Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Veradermics, Incorporated balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 59.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Veradermics, Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Veradermics, Incorporated (2023–2025)
The table below shows the annual total liabilities of Veradermics, Incorporated from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $273.63 Million | +5699.77% |
| 2024-12-31 | $4.72 Million | +22.93% |
| 2023-12-31 | $3.84 Million | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more